Nobiletin and isoliquiritigenin composition and application thereof
By developing pharmaceutical compositions of tangerine peel and isoglycerin, the adverse reactions and high cost problems of existing therapeutic drugs were solved, and effective treatment of diffuse interstitial pulmonary fibrosis was achieved, which significantly improved the survival rate of patients and Clinical prevention and treatment level.
Patent Information
- Application Number
- CN202411243100.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-15
AI Technical Summary
Existing diffuse interstitial fibrosis treatment drugs such as pirfenidone have adverse reactions and high costs, which are difficult to effectively alleviate the disease, and the patient's survival rate is low, so new therapeutic drugs need to be developed to improve the level of clinical prevention and treatment.
A pharmaceutical composition consisting of tangerine peel and isoglycerin was developed, its purity was determined by high performance liquid chromatography, and formulated as a pharmaceutical composition in different proportions for the prevention or treatment of diffuse pulmonary interstitial fibrosis.
The composition showed anti-inflammatory, antioxidant and inhibiting collagen deposition effects, significantly improved lung function and pathological performance in rats, and provided better therapeutic effects and economic and social benefits.
Smart Images

Figure BDA0005029864450000021 
Figure BDA0005029864450000022 
Figure BDA0005029864450000031
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drugs for treating diffuse pulmonary interstitial fibrosis, and relates to a composition of nobiletin and isoliquiritigenin and application thereof. Background Art
[0002] Diffuse pulmonary fibrosis is a group of diffuse lung diseases that involve the pulmonary interstitium and alveolar cavity, leading to the loss of alveolar-capillary functional units. It has high disability and mortality rates, heavy socioeconomic burdens, and serious harm to public health. The etiology of this disease is complex and may be related to dust, harmful fumes, infection, drugs, etc. The clinical manifestations are progressive dyspnea, restrictive ventilation disorders with reduced diffusion function, and eventually respiratory failure. Among them, the most representative is idiopathic pulmonary fibrosis (IPF).
[0003] IPF is the most common interstitial lung disease in clinical practice. It is more common in men than in women and is more common in the elderly. Its prognosis is poor and its incidence rate is increasing year by year. The prevalence of IPF in Italy, the United States, and the United Kingdom is 7.5-9.3 / 100,000, 14-42.7 / 100,000, and 10-25 / 100,000, respectively. The average survival time of IPF patients after diagnosis is 2.5-3.5 years. The survival rate of patients after diagnosis decreases significantly over time, with a 3-year survival rate of 50% and a 5-year survival rate of only 20%. IPF is characterized by diffuse alveolitis, alveolar structural disorder, and thickening of the pulmonary interstitium. Inflammation, oxidative stress, apoptosis, and epithelial-mesenchymal transformation are its main pathological mechanisms. Its pathological characteristics are mainly the accumulation of a large number of fibroblasts, deposition of extracellular matrix accompanied by inflammation and damage, which leads to changes in the normal lung tissue structure and loss of function. It mainly accumulates in the pulmonary interstitium, alveoli, and bronchioles, and can eventually lead to respiratory failure. Transforming growth factor (TGF)-β1 and interleukin (IL)-13 are important profibrotic factors that can promote fibrosis formation. Hydroxyproline (HYP) is the main component of collagen tissue, and its expression can reflect collagen deposition and the degree of pulmonary fibrosis.
[0004] In 2015, the American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association (ALAT) revised the 2011 IPF guidelines, pointing out that pirfenidone is a recommended medication, but its adverse reactions are wide-ranging. Even when the treatment benefit is assessed by forced vital capacity (FVC), some patients still cannot tolerate certain adverse reactions. In addition, the cost of pirfenidone treatment is high, making it difficult to promote clinically.
[0005] Therefore, it is necessary to further strengthen the research and development of drugs for the treatment of diffuse pulmonary fibrosis and improve the level and ability of clinical prevention and treatment. Summary of the invention
[0006] The inventor team has developed a pharmaceutical composition for the treatment of diffuse pulmonary interstitial fibrosis, which consists of ginsenoside Re, icariin, nobiletin, fritillarin A, paeoniflorin and isoliquiritigenin, and has submitted a patent application for the solution and obtained authorization CN109394776B. Based on the above research, the inventor further found that the Chinese medicine composition consisting of nobiletin and isoliquiritigenin can achieve better therapeutic effects, thus completing the present invention.
[0007] One aspect of the present invention provides a pharmaceutical composition consisting of nobiletin and isoliquiritigenin.
[0008] Nobiletin (CAS: 478-01-3, molecular formula: C 21 H 22 O8, molecular weight: 402.39g / mol) is as follows:
[0009]
[0010] Isoliquiritigenin (CAS: 961-29-5, molecular formula: C 15 H 12 O4, molecular weight: 256.25g / mol) is as follows:
[0011]
[0012] In the pharmaceutical composition according to the present invention, the ratio of nobiletin to isoliquiritigenin is not particularly limited, as long as a significant synergistic effect of the two can be achieved.
[0013] In some embodiments, in the pharmaceutical composition according to the present invention, the weight ratio of nobiletin to isoliquiritigenin can be 1:99 to 99:1, for example, 5:95 to 95:5, 10:90 to 90:10, 15:85 to 85:15, 15:85 to 60:40, 15:85 to 50:50, 15:85 to 40:60, or 15:85 to 30:70, for example, 15:85 to 25:75.
[0014] In some embodiments, in the pharmaceutical composition according to the present invention, the weight percentage of Nobiletin based on the total weight of the pharmaceutical composition can be more than 1%, more than 2%, more than 3%, more than 4%, more than 5%, more than 10%, or more than 15%, and less than 99%, less than 95%, less than 80%, less than 60%, less than 50%, less than 40%, less than 35%, less than 30%, or less than 25%, for example, 10% to 30%, or 15% to 25%, for example, 20%.
[0015] In some embodiments, in the pharmaceutical composition according to the present invention, the purity of nobiletin and isoliquiritigenin is not less than 98% as determined by high performance liquid chromatography. High performance liquid chromatography is a conventional determination method and a well-known technique, so its description is omitted here.
[0016] As demonstrated in the examples, the pharmaceutical composition according to the present invention can be used to prevent or treat diffuse pulmonary interstitial fibrosis, and can achieve better therapeutic effects compared with the pharmaceutical composition of CN109394776B.
[0017] Another aspect of the present invention provides use of the above-mentioned pharmaceutical composition for preparing a drug for preventing or treating diffuse pulmonary fibrosis.
[0018] Another aspect of the present invention provides a drug for preventing or treating diffuse pulmonary fibrosis, wherein the drug comprises the above-mentioned pharmaceutical composition.
[0019] In particular, the above-mentioned medicine does not contain ginsenoside Re, icariin, paeoniflorin, and fritillarin A.
[0020] Ginsenoside Re (CAS: 52286-59-6, molecular formula: C 48 H 82 O 18 , molecular weight: 947.154g / mol) has the following chemical structure:
[0021]
[0022] Icariin (CAS: 489-32-7, molecular formula: C 33 H 40 O 15 , molecular weight: 676.65g / mol) has the following chemical structure:
[0023]
[0024] Paeoniflorin (CAS: 23180-57-6, molecular formula: C 23 H 28 O 11 , molecular weight: 480.47g / mol) has the following chemical structure:
[0025]
[0026] Peimine (CAS: 23496-41-5, molecular formula: C 27 H45 The chemical structure of NO3 (molecular weight: 431.65 g / mol) is as follows:
[0027]
[0028] In another aspect, the present invention provides a method for preventing or treating diffuse pulmonary interstitial fibrosis, which comprises administering the pharmaceutical composition or the medicament according to the present invention to a subject in need thereof.
[0029] The object here can be a human or an animal, such as a mammal, such as a human, anthropoid, monkey, pig, horse, cow, sheep, dog, cat, lion, tiger, etc., but is not limited thereto.
[0030] The drug of the present invention can be in various dosage forms conventional in the art, such as solid, semisolid or liquid forms, and can be aqueous solutions, non-aqueous solutions, suspensions, lozenges, capsules, tablets, granules, pills and powders, etc. The administration route of the drug can be injection or oral administration. The injection can include intravenous injection, intramuscular injection, intraperitoneal injection, intradermal injection or subcutaneous injection.
[0031] The drug may include the pharmaceutical composition of the present invention in any amount, as long as the expected preventive or therapeutic benefit can be obtained. For example, based on mass percentage, the drug may include 0.01 to 99.99%, such as 1% to 90%, of the pharmaceutical composition of the present invention, and 99.99 to 0.01%, such as 99% to 10%, of a pharmaceutically acceptable excipient.
[0032] The pharmaceutically acceptable conventional excipients may be selected from excipients, fillers, diluents, preservatives, colorants, flavoring agents, flavoring agents, sustained-release agents, coating agents, penetration enhancers, adhesives, wetting agents, disintegrants, surfactants, lubricants, solubilizers, fragrances, extenders, buffers, soothing agents, etc., but are not limited thereto.
[0033] In addition, the drug of the present invention may further comprise other active ingredients according to the needs of treatment or complications, etc. The other active ingredients may be active ingredients for preventing or treating diffuse pulmonary fibrosis, or active ingredients of drugs for treating other diseases, disorders, or symptoms.
[0034] The dosage of the pharmaceutical composition and the drug according to the present invention can be selected according to the instructions for use, the patient's age, sex and other conditions and the severity of the disease.
[0035] The present invention has been described in detail above, but the above embodiments are only illustrative in nature and are not intended to limit the present invention. In addition, this article is not limited by any theory described in the above prior art or invention content or the following examples.
[0036] Unless otherwise expressly stated, the numerical ranges throughout the application documents include any subranges therein and any numerical values incremented by the smallest subunit of a given value therein. Unless otherwise expressly stated, the numerical values throughout the application documents represent approximate measurements or limitations of the range of embodiments including slight deviations from the given values and having approximately the values mentioned and having the exact values mentioned. Except for the working examples provided at the end of the detailed description, all numerical values of parameters (e.g., quantities or conditions) in this application document (including the appended claims) should be understood in all cases as modified by the term "approximately", regardless of whether "approximately" actually appears before the numerical value. "Approximately" means that the numerical value described allows for slight imprecision (some close to precision in the value; approximately or reasonably close to the value; approximately). If the imprecision provided by "approximately" is not understood in this ordinary sense in the art, the "approximately" used herein at least represents the variation that can be produced by ordinary methods of measuring and using these parameters. For example, "approximately" can include a variation of less than or equal to 10%, less than or equal to 5%, less than or equal to 4%, less than or equal to 3%, less than or equal to 2%, less than or equal to 1% or less than or equal to 0.5%.
[0037] Beneficial Effects
[0038] During the research and development, the inventors have obtained the same or similar results through repeated experiments. The method is effective and feasible, the raw materials are abundant, and it has good practical application value.
[0039] The composition for treating diffuse pulmonary interstitial fibrosis of the present invention is extracted and screened from tangerine peel and liquorice, has anti-inflammatory, anti-oxidative, collagen deposition inhibitory effects, and is effectively used for treating diffuse pulmonary interstitial fibrosis. The present invention repeatedly studies the efficacy of the composition obtained in each embodiment in treating rats with diffuse pulmonary interstitial fibrosis, and obtains satisfactory therapeutic effects.
[0040] The invention has abundant raw materials and a scientific and advanced method, and is effectively used for treating diffuse pulmonary interstitial fibrosis. It can be developed into a new drug for treating diffuse pulmonary interstitial fibrosis and has high economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1 In Example 1, H&E staining of lung tissue of rats in the blank group;
[0042] Figure 2 In Example 1, H&E staining of lung tissue of rats in the model group;
[0043] Figure 3 In Example 1, H&E staining of lung tissue of rats in the pirfenidone group;
[0044] Figure 4 In Example 1, H&E staining of rat lung tissue in Formula 1 group;
[0045] Figure 5 In Example 1, H&E staining of lung tissue of rats in Formulation 2 group;
[0046] Figure 6 In Example 1, H&E staining of lung tissue of rats in group 3 of formula;
[0047] Figure 7 In Example 1, H&E staining of lung tissue of rats in group 4 of formula;
[0048] Figure 8 In Example 1, H&E staining of lung tissue of rats in group 5 of formula;
[0049] Fig. 9 In Example 1, H&E staining of lung tissue of rats in group 6 of formula;
[0050] Fig.10 In Example 1, H&E staining of lung tissue of rats in group 7 of formula;
[0051] Fig.11 In Example 1, H&E staining of lung tissue of rats in group 8 of formula;
[0052] Fig.12 In Example 1, H&E staining of lung tissue of rats in group 9 of formula;
[0053] Fig.13 In Example 1, H&E staining of lung tissue of rats in group 10 of formula;
[0054] Fig.14 In Example 1, H&E staining of lung tissue of rats in group 11 of formula;
[0055] Fig.15 In Example 1, H&E staining of lung tissue of rats in group 12 of formula;
[0056] Fig.16 In Example 1, H&E staining of lung tissue of rats in group 13 of formula;
[0057] Fig.17 In Example 1, H&E staining of lung tissue of rats in group 14 of formula;
[0058] Fig.18 In Example 1, Masson staining of lung tissue of rats in the blank group;
[0059] Fig.19 In Example 1, Masson staining of lung tissue of rats in the model group;
[0060] Fig. 20In Example 1, Masson staining of lung tissue of rats in the pirfenidone group;
[0061] Fig.21 In Example 1, Masson staining of lung tissue of rats in Formula 1 group;
[0062] Fig. 22 In Example 1, Masson staining of lung tissue of rats in Formula 2 group;
[0063] Fig.23 In Example 1, Masson staining of lung tissue of rats in group 3 of formula;
[0064] Fig.24 In Example 1, Masson staining of lung tissue of rats in group 4 of formula;
[0065] Fig.25 In Example 1, Masson staining of lung tissue of rats in group 5 of formula;
[0066] Fig.26 In Example 1, Masson staining of lung tissue of rats in group 6 of formula;
[0067] Fig. 27 In Example 1, Masson staining of lung tissue of rats in group 7 of formula;
[0068] Fig.28 In Example 1, Masson staining of lung tissue of rats in group 8 of formula;
[0069] Fig.29 In Example 1, Masson staining of lung tissue of rats in group 9 of formula;
[0070] Fig.30 In Example 1, Masson staining of lung tissue of rats in group 10 of formula;
[0071] Fig.31 In Example 1, Masson staining of lung tissue of rats in group 11 of formula;
[0072] Fig.32 In Example 1, Masson staining of lung tissue of rats in group 12 of formula;
[0073] Fig.33 In Example 1, Masson staining of lung tissue of rats in group 13 of formula;
[0074] Fig.34 In Example 1, Masson staining of lung tissue of rats in group 14 of formula;
[0075] Fig.35 In Example 1, CoL I staining of lung tissue of rats in the blank group;
[0076] Fig.36 In Example 1, CoL I staining of lung tissue of rats in the model group;
[0077] Fig.37 In Example 1, CoL I staining of lung tissue of rats in the pirfenidone group;
[0078] Fig.38 In Example 1, CoLI staining of lung tissue of rats in Formula 1 group;
[0079] Fig.39 In Example 1, CoLI staining of lung tissue of rats in Formula 2 group;
[0080] Fig.40 In Example 1, CoLI staining of lung tissue of rats in group 3 of formula;
[0081] Fig.41 In Example 1, CoLI staining of lung tissue of rats in group 4 of formula;
[0082] Fig.42 In Example 1, CoL I staining of lung tissue of rats in group 5 of formula;
[0083] Fig.43 In Example 1, CoL I staining of lung tissue of rats in group 6 of formula;
[0084] Fig.44 In Example 1, CoL I staining of lung tissue of rats in group 7 of formula;
[0085] Fig.45 In Example 1, CoL I staining of lung tissue of rats in group 8 of formula;
[0086] Fig.46 In Example 1, CoL I staining of lung tissue of rats in group 9 of formula;
[0087] Fig.47 In Example 1, CoL I staining of rat lung tissue in group 10 of formula;
[0088] Fig.48 In Example 1, CoL I staining of lung tissue of rats in group 11 of formula;
[0089] Fig.49 In Example 1, CoL I staining of lung tissue of rats in group 12 of formula;
[0090] Fig.50 In Example 1, CoL I staining of lung tissue of rats in group 13 of formula;
[0091] Fig.51 In Example 1, CoLI staining of lung tissue of rats in group 14 of formula;
[0092] Fig.52 In Example 1, α-SMA staining of lung tissue of rats in the blank group;
[0093] Fig.53 In Example 1, α-SMA staining of lung tissue of rats in the model group;
[0094] Fig.54 In Example 1, α-SMA staining of lung tissue of rats in the pirfenidone group;
[0095] Fig.55 In Example 1, α-SMA staining of rat lung tissue in Formula 1 group;
[0096] Fig.56 In Example 1, α-SMA staining of lung tissue of rats in Formula 2 group;
[0097] Fig.57 In Example 1, α-SMA staining of lung tissue of rats in group 3 of formula;
[0098] Fig.58 In Example 1, α-SMA staining of lung tissue of rats in group 4 of formula;
[0099] Fig.59 In Example 1, α-SMA staining of lung tissue of rats in group 5 of formula;
[0100] Fig.60 In Example 1, α-SMA staining of lung tissue of rats in group 6 of formula;
[0101] Fig.61 In Example 1, α-SMA staining of lung tissue of rats in group 7 of formula;
[0102] Fig.62 In Example 1, α-SMA staining of lung tissue of rats in group 8 of formula;
[0103] Fig.63 In Example 1, α-SMA staining of lung tissue of rats in group 9 of formula;
[0104] Fig.64 In Example 1, α-SMA staining of rat lung tissue in group 10 of formula;
[0105] Fig.65 In Example 1, α-SMA staining of rat lung tissue in group 11 of formula;
[0106] Fig.66 In Example 1, α-SMA staining of lung tissue of rats in group 12 of formula;
[0107] Fig.67In Example 1, α-SMA staining of lung tissue of rats in group 13 of formula;
[0108] Fig.68 In Example 1, α-SMA staining of lung tissue of rats in group 14 of formula. DETAILED DESCRIPTION
[0109] The specific embodiments of the present invention are further described in detail below in conjunction with the examples. However, the following examples are provided only for easier understanding of the present invention, and the scope of the present invention is not limited thereto.
[0110] Example 1 Screening of pharmaceutical composition formulations
[0111] 1 Experimental Materials
[0112] 1.1 Experimental animals
[0113] SPF grade SD rats, half male and half female (age: 6-8 weeks old, weight: 200 ± 10 g; animal license number: 37009200018733) were purchased from Jinan Pengyue Experimental Animal Breeding Co., Ltd. (SCXK [Lu] 20140007).
[0114] 1.2 Experimental drugs
[0115] 1.2.1 Bleomycin hydrochloride for injection (production batch number: s1214-12, 15U / bottle, Hisun Ruihui Pharmaceutical Co., Ltd.), dissolved in normal saline to a concentration of 30mg / ml.
[0116] 1.2.2 Pirfenidone capsules (Aisiri, 100 mg × 54 capsules / bottle, Beijing Contini Pharmaceutical Co., Ltd.), positive control drug, were prepared with distilled water to a concentration of 33.3 mg / ml.
[0117] 1.2.3 Icariin, isoliquiritigenin, fritillarin A, chuanxiongpirin, paeoniflorin and ginsenoside were purchased from Chengdu Munster Biotechnology Co., Ltd. The above monomers were determined by high performance liquid chromatography, and the purity was higher than 98%. Before use, a 0.5wt% sodium carboxymethyl cellulose (Sodium carboxymethyl cellulose, CMC-Na) aqueous solution (hereinafter referred to as 0.5% sodium carboxymethyl cellulose) was used to prepare a suspension.
[0118] 1.3 Experimental reagents
[0119] 1.3.1 Immunohistochemistry (IHC) related reagents
[0120] SABC ready-to-use rabbit IgG immunohistochemistry kit (SA1022), DAB color development kit (AR1022), and Mayor's hematoxylin (AR0005) were provided by Wuhan Boster Biotechnology Co., Ltd.
[0121] The primary antibodies rabbit anti-rat Anti-Collagen I (COL1) Antibody (Cat. No. AF7001), Anti-Collagen III (COLIII) Antibody (Cat. No. AF0136), and Anti-alpha-SMA (α-SMA) Antibody (Cat. No. AF1032) were provided by Affinity Biopharmaceuticals, Inc., USA.
[0122] α-SMA (14395-1-AP) polyclonal antibody was provided by Wuhan Sanying Biotechnology Co., Ltd.
[0123] 1.3.2Hematoxylin-eosin (H&E) staining, Masson's Trichrome staining related reagents
[0124] Paraformaldehyde (P804536) was provided by Shanghai MacLean Biochemical Technology Co., Ltd. (Shanghai, China).
[0125] Paraffin wax (39601006) was provided by Leica Microsystems Trading, Inc. (Illinois, USA).
[0126] Anhydrous ethanol (500 ml) and xylene (500 ml) were provided by Tianjin Zhiyuan Chemical Reagent Co., Ltd.
[0127] Hematoxylin staining solution (G1140), eosin staining solution (G1100), and neutral gum (G8590) were provided by Beijing Solebow Technology Co., Ltd.
[0128] Masson stain (G1006) was provided by Wuhan Saiweier Biotechnology Co., Ltd.
[0129] 1.4 Experimental instruments
[0130] The experimental instruments are shown in Table 1.
[0131] Table 1
[0132]
[0133] 2 Research Methods
[0134] 2.1 Model preparation
[0135] The rats were acclimatized to the environment for 7 days after purchase. They were kept in individual ventilated cages (IVC) and maintained at a temperature of (20-25)°C, relative humidity of (50±10)%, ventilation of 15 times / h, and ammonia concentration of ≤14 mg / m 3 , Noise level 60 ≤ db, maintain 12h day and night cycle. Regularly check the purification and water and electricity operating systems to keep the environment quiet.
[0136] A rat model of pulmonary fibrosis was prepared by a one-time intratracheal instillation of bleomycin. After the rats were anesthetized by intraperitoneal injection of 10% chloral hydrate (3.0 ml / kg), they were tilted back and fixed on a mouse board. The light source was irradiated on the throat, and the tongue was gently pulled to open the mouth. The glottis could be seen to open and close in an orderly manner with breathing. The indwelling needle was gently pushed into the trachea as the glottis opened and closed, and the needle core was pulled out. The swing of the cotton thread could be used to verify whether the tracheal intubation was successful. Bleomycin was injected into the trachea at a rate of 5 mg / kg, and 0.5 ml of air was continued to be injected to ensure the depth of the drug. The rats were stood upright and shaken from side to side to ensure that the drug was evenly distributed in the lungs. The anesthetized rats were placed on an electric blanket to maintain body temperature and placed in the corresponding mouse cage after waking up. The rats were raised normally until the 28th day, and they were free to drink pure water and sterile feed every day.
[0137] 2.2 Processing
[0138] The rats were randomly divided into groups, with 12 rats in each group, 6 female rats in each group and 6 male rats in each group. The modeling day was set as day 0. From day 29, the blank group (normal rats without modeling) and the model group were given normal saline by gavage (2 ml / rat), and the pirfenidone group was given pirfenidone solution by gavage (108 mg kg -1 d -1 ), each formulation group was gavaged once a day for 14 days, and samples were collected after the 42nd day.
[0139] The drug dose is calculated using the following equivalent dose coefficient conversion formula:
[0140] D 大鼠 =D people × (HI 大鼠 / HI 人 )×(W 大鼠 / W 人 ) 2 / 3
[0141] Where, D: dose, HI: body type index, W: body weight.
[0142] 2.3 Index detection
[0143] 2.3.1 General:
[0144] Observe the death of rats, bleeding around the eyes, mouth and nose. Observe the fur color, mental state, eating and activity of rats every day.
[0145] 2.3.2 Lung function:
[0146] Before sampling, the rats were anesthetized, tracheotomy was performed, and a tracheal tube was inserted into the rat trachea and fixed. TM The series PFT measurement system was used to detect the forced vital capacity (FVC), forced expiratory volume in 0.3s (FEV 0.3), inspiratory capacity (IC), and dynamic lung compliance (Cydn) of rats.
[0147] 2.3.3 Lung tissue pathology:
[0148] The left lung was fixed with 10% formaldehyde for 72 h, embedded in paraffin, and sectioned at 4 μm for HE and MASSON staining.
[0149] The pathological scores of alveolitis and pulmonary fibrosis were calculated according to the Szapiel method. The degree of alveolitis was detected by HE staining, and the degree of pulmonary fibrosis was detected by MASSON staining.
[0150] The pathological changes of lung tissue were observed under an optical microscope. Six sections were selected from each group and six fields of view were selected from each section. The degree of alveolitis and pulmonary fibrosis was scored according to the standards shown in Table 2.
[0151] Table 2 Grading and scoring criteria for alveolitis and pulmonary fibrosis
[0152]
[0153] 2.3.4 Expression of COLI and α-SMA in lung tissue:
[0154] Immunohistochemistry was used for detection.
[0155] The lung tissue was sliced at 4 μm and baked at 60°C for 3 h. The paraffin sections were dewaxed in xylene, dehydrated with alcohol gradient, and washed with distilled water for 2 min. Antigen retrieval was performed by boiling 0.01 M citrate buffer in a microwave oven. 3% hydrogen peroxide was added to the sections to block endogenous peroxidase. The sections were blocked with 5% BSA blocking solution and incubated at 37°C for 30 min. Primary antibodies were added (the dilution ratio of COLⅠ was 1:500 and the dilution ratio of α-SMA was 1:2000) and incubated at 4°C. Incubate overnight in a wet box; add HRP-labeled goat anti-rabbit secondary antibody and incubate at 37°C for 20 min; add SABC and incubate at 37°C for 30 min, add freshly prepared DAB color developing solution and observe under a microscope. Stop color development when it turns brown-yellow; counterstain with hematoxylin for 30 s and differentiate with 1% hydrochloric acid alcohol for 3 s; dehydrate in gradient alcohol in sequence; air-dry in a fume hood, seal with neutral gum and air-dry; collect images under an Olympus-DP70 microscope (Image-Pro Plus 6.0, IPP 6.0), randomly select 6 fields of view for each slice, and calculate the image integral optical density (IOD).
[0156] 2.4 Statistical methods
[0157] IBM SPSS22.0 statistical software was used for data analysis. Chi-square test was used for count data; repeated measurement data of rat body weight and lung function were analyzed by repeated measurement analysis of variance; one-way ANOVA was used for comparison between groups, and the least significant difference method was used for equal variance, and Dunnett's T3 method was used for unequal variance. The significance level was α = 0.05, and the data were expressed as mean. Means are ± standard error (SE).
[0158] 2.5 Comprehensive evaluation of R value
[0159] The R value comprehensive evaluation method (copyright number: Guozuo Dengzi-2013-A-00096833) was used to comprehensively evaluate the rat lung function (forced expiratory vital capacity (FVC), forced expiratory volume in 0.3 seconds (FEV0.3), deep inspiratory capacity (IC), dynamic lung compliance (Cydn), lung tissue pathology (HE staining, MASSON staining), lung tissue immunohistochemistry COL I, α-SMA and other indicators.
[0160] Standardize the data and build R 综合 Value dataset (R 综合 =R-(-2)), after statistical analysis, the comprehensive correction effect R 综合 When R 综合When R <1, it means that the comprehensive correction strength of the drug on such indicators exceeds the normal value. 综合 =1 means that the drug has the best comprehensive correction effect on such indicators. <R 综合 When R <2, it means that the drug has a certain corrective effect on such indicators. 综合 =2 means that the drug has no corrective effect on such indicators. 综合 >2 indicates that the drug has a reverse exacerbating effect on such indicators. 综合 The size of the drug is used to obtain the order of the comprehensive effect of the drug on the indicators.
[0161] 3. Formulation screening
[0162] The inventors screened based on the drug composition formula in CN109394776B and optimized the drug composition formula therein to detect the therapeutic effect of the formula obtained by simplifying the formula or reducing the dosage.
[0163] The inventors first confirmed through preliminary optimization experiments that the formula obtained by not using or using less of some components (for example, ginsenosides and / or Fritillaria cirrhosa) in the pharmaceutical composition formula in CN109394776B still has the therapeutic effect of treating rats with diffuse pulmonary fibrosis, and used the R value comprehensive evaluation method to confirm that some formulas have better correction intensity effects.
[0164] Based on the above experiments, the inventors further combined the components in the above-mentioned pharmaceutical composition formula to obtain a new formula and treated the rats in groups according to the dosage. The specific formula and dosage are shown in Table 3.
[0165] Table 3 Experimental groups and compatibility
[0166]
[0167] Each composition was provided and identified by the Drug Analysis Laboratory of the School of Pharmacy of Henan University of Traditional Chinese Medicine, and was prepared into a suspension in 0.5% sodium carboxymethyl cellulose before use.
[0168] Table 4 Grouping and treatment
[0169]
[0170] 4 Experimental results
[0171] 4.1 General
[0172] The rats in the blank group moved freely, reacted quickly, had smooth and shiny fur, and ate and drank normally.
[0173] On the first day of modeling, the rats in the model group showed significantly reduced activity, mental fatigue, sleepiness, and significantly reduced diet and water intake, but no death; in the first week after modeling, there was bleeding around the eyes, mouth, nose, and nails, and blood scabs were seen. Diet and water intake recovered, but not to normal. In the second week after modeling, there was no bleeding in the rats in the model group, and the diet and water intake returned to normal. The fur was white and dull, and some rats showed sneezing symptoms. In the third to fourth weeks after modeling, the rats in the model group moved freely, and the diet and water intake were normal.
[0174] After the 5th to 6th week of administration, the pirfenidone group and each formulation group were able to improve the above symptoms to varying degrees.
[0175] 4.2 Lung function
[0176] The results of pulmonary function monitoring are shown in Table 4.
[0177] Table 4 Lung function related indicators
[0178]
[0179] Note 1: N = 10, compared with the blank group: # P<0.05, ## P<0.01; compared with the model group: π P<0.05, ππ P<0.01; compared with pirfenidone group: *P<0.05, **P<0.01; compared with formula 1: ▲ P<0.05, ▲▲ P<0.01; compared with formula 2: △ P<0.05, △△ P<0.01.
[0180] Compared with the blank group, FVC, FEV0.3, IC, and Cydn in the model group were significantly decreased (P<0.01, P<0.05).
[0181] Compared with the model group, the FVC of formula 7, 8, and 9 was significantly increased (P<0.01, P<0.05); the FEV0.3 of formula 1, 7, 8, and 9 was significantly increased (P<0.01, P<0.05); the IC of formula 1, 7, 8, 9, and 12 was significantly increased (P<0.05); and the Cydn of formula 5, 8, 12, and 14 was significantly increased (P<0.05).
[0182] Compared with the pirfenidone group, the FVC and FEV0.3 of formulations 7, 8, and 9 were significantly increased (P<0.01).
[0183] Compared with formula 1 (Jinshui slow-fiber component formula I), the FVC of formulas 7, 8, and 9 were significantly increased (P<0.01).
[0184] Compared with formula 2 (Jinshui slow-fiber formula II), the FEV0.3 of formulas 7, 8, and 9 were significantly increased (P<0.01).
[0185] 4.3 Lung tissue pathology
[0186] H&E staining of lung tissues of rats in each group is shown in Figures 1 to 17 , MASSON staining diagram see Figure 18-34 .
[0187] As can be seen from the figure, the alveolar structure of the rats in the blank group was intact, and the alveolar septa were not thickened. The alveolar walls of the rats in the model group were broken and fused, and alveolar cavities of different sizes were visible. The alveolar structure was obviously destroyed, the alveolar walls were widened, there were a large number of inflammatory cells infiltrated, collagen deposition increased, and fibrotic scars formed. The pirfenidone group and each formula group improved the above pathological damage to varying degrees.
[0188] The results of H&E staining and MASSON staining are shown in Table 5. Compared with the blank group, the H&E staining and MASSON staining scores of the model group were significantly increased (P<0.01). Compared with the model group, the H&E staining pathological scores of formulas 3, 6, 8, 9, and 12 were significantly reduced (P<0.01, P<0.05); the MASSON staining pathological scores of formulas 7, 8, 9, 11, and 12 were significantly reduced (P<0.01, P<0.05).
[0189] Table 5 Alveolitis and pulmonary fibrosis scores
[0190]
[0191] Same as note 1.
[0192] 4.4 Positive expression of ColⅠ and α-SMA in lung tissue
[0193] ColⅠ staining of lung tissue is shown in Figures 35 to 51 , α-SMA staining diagram is shown in Figures 52 to 68 .
[0194] The results of the positive expression of ColⅠ and α-SMA in lung tissue are shown in Table 6.
[0195] Compared with the blank group, the protein expressions of COLⅠ and α-SMA in the lung tissue of the rats in the model group were significantly increased (P<0.01, P<0.05). Compared with the model group, the positive expression of COLⅠ in the pirfenidone group and formulas 1, 2, 4, 7, 8, 9, 12, and 13 was significantly decreased (P<0.01, P<0.05); the positive expression of α-SMA in formulas 5, 6, and 8 was decreased (P<0.05).
[0196] Table 6 Changes of COL1 and α-SMA in each group
[0197]
[0198] Same as Note 1. N=6.
[0199] 4.6 Comprehensive evaluation of R value
[0200] The R value comprehensive evaluation method was used to calculate 8 indicators including lung function (FVC, FEV0.3, IC, Cydn), lung tissue pathology (H&E staining, MASSON staining), and collagen deposition (COLⅠ, α-SMA). The results are shown in Table 7.
[0201] Table 7 R values of overall efficacy related indicators
[0202]
[0203] Same as note 1.
[0204] The results showed that formulas 1, 7, 8, and 9 all had significant corrective effects on PF rats (P<0.05, P<0.01). Formula 8 showed the best correction intensity of the total index (P<0.01).
[0205] 5. Conclusion
[0206] Each formula can improve the lung function and manifestations of lung fibrosis in rats with pulmonary fibrosis to varying degrees, reduce inflammatory response and collagen deposition in lung tissue, among which formula 8 (isoliquiritigenin combined with nobiletin) has a more significant efficacy and is more economical.
[0207] In summary, Formula 8 has a good therapeutic effect in the treatment of pulmonary fibrosis. It can alleviate symptoms, improve lung function, improve the degree of alveolitis and pulmonary fibrosis in lung tissue, reduce collagen deposition in lung tissue, and can effectively alleviate the progression of pulmonary fibrosis. Formula 8 has the advantages of clear ingredients, small dosage form, and easy to carry. It is an innovation in the long-term treatment of pulmonary fibrosis and has high practical value.
[0208] The embodiments described above are only preferred embodiments of the present invention and are not intended to limit the present invention in any form. Although the present invention has been disclosed as a preferred embodiment as above, it is not intended to limit the present invention. Any technician familiar with the profession can make some changes or modifications to equivalent embodiments of equivalent changes using the technical contents disclosed above without departing from the scope of the technical solution of the present invention. However, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are within the scope of the technical solution of the present invention.
Claims
1. A pharmaceutical composition consisting of nobiletin and isoliquiritigenin.
2. The pharmaceutical composition according to claim 1, wherein The weight ratio of nobiletin to isoliquiritigenin is 1:99 to 99:1, such as 10:90 to 90:10, 15:85 to 85:15, 15:85 to 40:60, or 15:85 to 30:70, such as 15:85 to 25:
75.
3. The pharmaceutical composition according to claim 1, wherein The weight percentage of nobiletin is more than 1%, more than 5%, more than 10%, or more than 15%, and less than 99%, less than 60%, less than 40%, less than 30%, or less than 25%, such as 10% to 30%, or 15% to 25%.
4. The pharmaceutical composition according to claim 1, wherein The purity of the nobiletin and isoliquiritigenin is not less than 98% as determined by high performance liquid chromatography.
5. Use of the pharmaceutical composition according to any one of claims 1 to 4 for preparing a medicament for preventing or treating diffuse pulmonary fibrosis.
6. A drug for preventing or treating diffuse pulmonary fibrosis, comprising the pharmaceutical composition according to any one of claims 1 to 4, but excluding ginsenoside Re, icariin, paeoniflorin, and fritillarin A.
